- Bradford Cross, Chief
Technology Officer to transition; Don
Gehlert, PhD, Chief Scientific Officer to transition to
Senior Scientific Advisor -
NEW YORK, Dec. 29, 2021 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the
"Company"), a leading biotech company developing
psychedelic-inspired therapies, today announced that its Chief
Technology Officer, Bradford Cross,
has transitioned from his role.
"On behalf of the Board of Directors and Executive team, I would
like to thank Bradford for his contributions to the Company and
wish him all the best in his future endeavors," said Robert Barrow, Chief Executive Officer and
Director of MindMed. "We remain dedicated to advancing our pipeline
and ongoing digital therapeutics platform forward under the
leadership of MindMed Chief Medical Officer, Dr. Daniel Karlin. We enter 2022 well positioned
both financially and strategically to continue on our mission to
transform mental health treatment."
Additionally, Don Gehlert, PhD
will be transitioning from his role as CSO and will continue as a
Senior Scientific Advisor. Mr. Barrow added "Don has been and
will continue to be an integral part of our organization.
While this represents a change in his title, our entire team will
continue to work closely with Don and benefit from his incredible
breadth of experience in developing innovative CNS
therapeutics."
About MindMed
MindMed is a clinical-stage biotech company that seeks to
discover, develop and deploy psychedelic-inspired medicines and
therapies to address addiction and mental illness. The Company is
assembling a compelling drug development pipeline of innovative
treatments based on psychedelic substances including psilocybin,
LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed
executive team brings extensive biopharmaceutical experience to
MindMed's approach to developing the next generation of
psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Safe Harbor Statement
This press release contains
forward-looking statements. These statements are made under the
"safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Statements that are not historical facts,
including statements about the Company's beliefs and expectations,
are forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and a number of factors could
cause actual results to differ materially from those contained in
any forward-looking statement. In some cases, forward-looking
statements can be identified by words or phrases such as "may",
"will," "expect," "anticipate," "target," "aim," "estimate,"
"intend," "plan," "believe," "potential," "continue," "is/are
likely to" or other similar expressions. Further information
regarding these and other risks, uncertainties or factors is
included in the Company's filings with the SEC. All information
provided in this press release is as of the date of this press
release, and the Company does not undertake any duty to update such
information, except as required under applicable law.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-announces-transitions-to-management-team-301451408.html
SOURCE Mind Medicine (MindMed) Inc.